Vertex Pharmaceuticals (NASDAQ:VRTX) Pulls Back 6.9% This Week, but Still Delivers Shareholders Strong 34% CAGR Over 3 Years
Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock
Vertex Trust Sells $3.79 Million in Shares
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560
Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $486
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575